id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ajcp-747	Yasser, Sadawey; Hesham, Metwally	Empagliflozin-Induced Acute Pancreatitis and Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus	2022	5	.pdf	application/pdf	2131	133	52	A recent family of anti-diabetic medications known as SGLT2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin) increases the likelihood of euglycemic DKA discrete to the length of treatment (Peters et al., 2015; Somagutta et al., 2021; Taylor et al., 2015). Rates of DKA-related occurrences among type 2 diabetic patients on SGLT2 inhibitors ranged from 0.16 to 0.76 events per 1000 patient years (Goldenberg et al., 2016).SGLT2 inhibitors raise the risk of DKA in T2D https://journals.e-palli.com/home/index.php/ajcp	cache/ajcp-747.pdf	txt/ajcp-747.txt